Salix Pharmaceuticals, Ltd.

393 articles about Salix Pharmaceuticals, Ltd.

• Salix Announces 2023 Gastrointestinal Health Scholars Program Winners

  7/11/2023

  Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program.

• Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023

  5/8/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today will deliver a podium presentation of its research titled "Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs" during Digestive Disease Week® (DDW) 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023.

• Salix Partners with the Colorectal Cancer Alliance on Community Screening Program

  4/24/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced a partnership with the Colorectal Cancer Alliance, the nation's nonprofit leader dedicated to combatting colorectal cancer, to increase awareness and access to preventative colorectal screenings in medically underserved communities.

• New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider

  4/4/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced the results from the third edition of its patient perspectives survey, an annual survey of U.S. adults living with irritable bowel syndrome or chronic idiopathic constipation.

• Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider

  12/1/2022

  Salix Pharmaceuticals today announced the launch of a series of social media and digital initiatives to raise awareness during Constipation Awareness Month in December.

• Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting

  10/24/2022

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today announced four posters and one abstract featuring data for XIFAXAN (rifaximin), TRULANCE (plecanatide) and RELISTOR (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.

• Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population

  10/12/2022

  Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc., released the Salix Liver Health Annual Trends Report, Second Edition with the latest information on chronic liver disease care and findings that include a continued rise in hospitalizations and mortality from CLD and cirrhosis, as well as gaps in care and knowledge that may prevent early diagnosis and optimal management of CLD, cirrhosis and its complications.

• SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY

  10/3/2022

  Bausch Health Companies Inc. announced today, their endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain.

• Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)

  8/10/2022

  Bausch Health Companies Inc. today announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.  

• 

  Axcella Shifts Focus to Long COVID, NASH Amid Leadership Losses

  5/27/2022

  Axcella is prioritizing its clinical development portfolio to focus on its investigative assets for COVID-19 and non-alcoholic steatohepatitis (NASH) after abrupt leadership resignations.

• Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

  5/18/2022

  Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022.

• Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month

  12/3/2021

  Bausch Health Companies Inc. today introduced a collection of digital and social activations aimed at helping adult patients with opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

• Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021

  11/11/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals announced two abstracts featuring new data for rifaximin are being presented at The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases, which is taking place virtually Nov. 12-15, 2021.

• Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting

  10/25/2021

  Research Findings for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) Will be Presented

• New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States

  10/25/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal and liver diseases, released key findings from a survey of health care providers treating chronic liver disease, including potential gaps in prevention and diagnosis efforts.

• Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

  9/2/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced that new Health Economic Outcomes Research data featuring RELISTOR® will be shared at PAINWeek 2021 taking place in Las Vegas from Sept.

• Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

  7/22/2021

   Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program.

• Salix Will Feature New Data At Digestive Disease Week® 2021

  5/17/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced four scientific poster presentations featuring data for XIFAXAN®, TRULANCE® and PLENVU® to be shared at Digestive Disease Week® 2021, which takes place virtually May 21-23, 2021.

• Salix Announces 2021 Gastrointestinal Health Scholars Program

  2/18/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced the opening of the application period for the 2021 Salix Gastrointestinal Health Scholars Program.

• Salix To Present Data At AASLD's The Liver Meeting Digital Experience

  11/11/2020

  Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointes